ESMO IOTECH
@esmo_iotech
IOTECH publishes pre-clinical & clinical studies covering natural & therapy-induced innate & adaptive immune responses against solid/haematological cancers
ID: 1437710641402368003
https://www.esmoiotech.org/ 14-09-2021 09:31:58
163 Tweet
351 Followers
159 Following
๐ There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: Alena Gros & @sklobuch. For further details, please check out: spkl.io/60164sUYj
Congratulations to our ESMO IOTECH's Editor-in-Chief John Haanen for the 2024 ESMO Lifetime Achievement Award ๐ . Well-deserved distinction, and we are all so delighted! #ESMO24 ESMO - Eur. Oncology
๐ Latest REVIEW by Olivera & Ignacio Melero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'. Available #OpenAccess ๐ esmoiotech.org/article/S2590-โฆ
๐ข Check out this latest original article by van Duin & colleagues - a multicentre study ๐ณ๐ฑ. ๐ฌ Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma. Available #OpenAccess ๐ esmoiotech.org/article/S2590-โฆ
๐ก Presenting your work at #ESMO24 in Barcelona ๐ช๐ธ? Looking for a home for your research work? Consider submitting to ESMO IOTECH ๐ ๐ esmoiotech.org
๐ข Hear first hand from our Editor-in-Chief Prof John Haanen about ESMO IOTECH - ESMO - Eur. Oncologyโs peer-reviewed open-access specialised journal dedicated to publishing advances in immuno-oncology and technology ๐
๐ข Check out this latest original article by Yeghaian, Stefano Trebeschi + colleagues ๐ณ๐ฑ๐จ๐ญ๐ฉ๐ฐ. ๐ฌ Integrated noninvasive dx for prediction of survival in immunotherapy: Longitudinal CT, blood tests & clinical parameters โถ๏ธ AI models. Available #OpenAccess ๐ esmoiotech.org/article/S2590-โฆ
๐ข Check out this latest original article by Tanja de Gruijl & team Amsterdam UMC. ๐งซAn organotypic human melanoma-in-skin model as an inย vitro tool for testing Vฮณ9Vฮด2-T cell-based immunotherapy. Available #OpenAccess ๐ esmoiotech.org/article/S2590-โฆ
Discover what's in store for Immuno-Oncology and Technology! Watch our video to learn about our article types, the submission process, and what you can expect as an author or reader. Find out more spkl.io/6018fOAbi ESMO IOTECH
.Ton Schumacher Lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 December 2024 at the opening session of #ESMOImmuno24. ๐ow.ly/FiiN50U0iab
๐ข Check out this special case report by Monberg, Svane & colleagues CCIT-DK: National Center for Cancer Immune Therapy University of Helsinki Rigshospitalet ๐ฉ๐ฐ๐ซ๐ฎ. ๐Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess ๐esmoiotech.org/article/S2590-โฆ
๐ข Check out this original article by Konรฏg & colleagues University of Basel UniSpitalBaselCH ๐จ๐ญ. ๐ BaseTIL trial: A single-center investigator-initiated phase I study of TILs + nivolumab in patients with advanced melanoma. Available #OpenAccess ๐ esmoiotech.org/article/S2590-โฆ
#ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy.โฏHowever, some challenges still limit its implementation in #ClinicalPractice. #ESMODailyReporter #ESMO-GROW Marco Donia ๐ow.ly/rwXC50UoUCo
Welcome to Geneva ๐จ๐ญ for the much awaited #ESMOImmuno24! ๐ก Presenting your work at #ESMOImmuno24? Looking for a home for your research work? Consider submitting to ESMO IOTECH: ๐ esmoiotech.org
It's finally here! #ESMOImmuno24 ๐ Delighted that all accepted abstracts, including late-breaking abstracts, will be published online in the 'ESMO Immuno-Oncology Congress 2024 Abstract Book', a supplement to ESMO IOTECH.
#ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher Lab, tackling the T-cell receptor challenge w/ vast datasets and cutting-edge high-throughput methods may pave the way for advances in #immunotherapy. #ESMODailyReporter ๐ow.ly/rZUO50Up0BE
